Cargando…
Guillain-Barre syndrome in 220 patients with COVID-19
This review summarises and discusses recent findings concerning the pathophysiology, clinical presentation, diagnosis, treatment, and outcome of SARS-CoV-2-associated Guillain-Barre syndrome (SC2-GBS). By the end of December 2020, at least 220 patients with SC2-GBS have been published in 95 papers....
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8094972/ https://www.ncbi.nlm.nih.gov/pubmed/33967575 http://dx.doi.org/10.1186/s41983-021-00310-7 |
_version_ | 1783688009796812800 |
---|---|
author | Finsterer, Josef Scorza, Fulvio A. |
author_facet | Finsterer, Josef Scorza, Fulvio A. |
author_sort | Finsterer, Josef |
collection | PubMed |
description | This review summarises and discusses recent findings concerning the pathophysiology, clinical presentation, diagnosis, treatment, and outcome of SARS-CoV-2-associated Guillain-Barre syndrome (SC2-GBS). By the end of December 2020, at least 220 patients with SC2-GBS have been published in 95 papers. SC2-GBS is most likely secondary due to an immune reaction against SARS-CoV-2 since the virus has not been found in the CSF of any SC2-GBS patient so far reported. SC2-GBS occurs in each age group and does not differ from non-SC2-GBS regarding clinical presentation and treatment, but the outcome of SC2-GBS is worse compared to non-CS2-GBS patients, and the prevalence/incidence of GBS most likely increased since the outbreak of the pandemic. Early diagnosis of SC2-GBS is warranted to apply appropriate treatment in due time and to improve the overall outcome from the infection. |
format | Online Article Text |
id | pubmed-8094972 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-80949722021-05-05 Guillain-Barre syndrome in 220 patients with COVID-19 Finsterer, Josef Scorza, Fulvio A. Egypt J Neurol Psychiatr Neurosurg Review This review summarises and discusses recent findings concerning the pathophysiology, clinical presentation, diagnosis, treatment, and outcome of SARS-CoV-2-associated Guillain-Barre syndrome (SC2-GBS). By the end of December 2020, at least 220 patients with SC2-GBS have been published in 95 papers. SC2-GBS is most likely secondary due to an immune reaction against SARS-CoV-2 since the virus has not been found in the CSF of any SC2-GBS patient so far reported. SC2-GBS occurs in each age group and does not differ from non-SC2-GBS regarding clinical presentation and treatment, but the outcome of SC2-GBS is worse compared to non-CS2-GBS patients, and the prevalence/incidence of GBS most likely increased since the outbreak of the pandemic. Early diagnosis of SC2-GBS is warranted to apply appropriate treatment in due time and to improve the overall outcome from the infection. Springer Berlin Heidelberg 2021-05-04 2021 /pmc/articles/PMC8094972/ /pubmed/33967575 http://dx.doi.org/10.1186/s41983-021-00310-7 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Review Finsterer, Josef Scorza, Fulvio A. Guillain-Barre syndrome in 220 patients with COVID-19 |
title | Guillain-Barre syndrome in 220 patients with COVID-19 |
title_full | Guillain-Barre syndrome in 220 patients with COVID-19 |
title_fullStr | Guillain-Barre syndrome in 220 patients with COVID-19 |
title_full_unstemmed | Guillain-Barre syndrome in 220 patients with COVID-19 |
title_short | Guillain-Barre syndrome in 220 patients with COVID-19 |
title_sort | guillain-barre syndrome in 220 patients with covid-19 |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8094972/ https://www.ncbi.nlm.nih.gov/pubmed/33967575 http://dx.doi.org/10.1186/s41983-021-00310-7 |
work_keys_str_mv | AT finstererjosef guillainbarresyndromein220patientswithcovid19 AT scorzafulvioa guillainbarresyndromein220patientswithcovid19 |